Oramed Pharmaceuticals has started recruiting patients for a new clinical trial of ORMD-0801, an orally ingestible insulin capsule, for patients with type 1 diabetes mellitus (T1DM) in Israel.
The company is also conducting ORMD-0801 US FDA trial for the treatment of type 2 diabetes. Oramed CEO Nadav Kidron said, “We are very excited to continue our development of ORMD-0801 for this high-need indication.
“We have been encouraged by our successful T1DM trials to date and we look forward to the commencement of this study.”
According to previous clinical studies, ORMD-0801 administered to T1DM patients just before a meal effectively kept their blood sugar levels stable.